250 research outputs found
Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children.
No full textDiagnostic effectiveness of simultaneous thyroxine and thyroid-stimulating hormone screening measurements. Thirteen years' experience in the Northeast Italian Screening Programme
No full textObjectives: To evaluate the effectiveness of thyroid-stimulating hormone (TSH) and thyroxine (T4) measurements at neonatal screening for congenital hypothyroidism, we compared our false-negative results with those we would have obtained if we had used TSH screening alone.Subjects and methods: Between January 1989 and December 2001 745,258 newborns were screened (98.3% of total born) for congenital hypothyroidism in northeast Italy. T4 and TSH were measured simultaneously on blood spots collected after birth. Between 1989 and 1998, semi-quantitative total T4 (tT4) and TSH concentrations were measured by radiolabelled immunological assay and, from 1999 to 2001, using time-resolved fluorometer Delfia instruments (EG&G Wallac Oy, Finland) and fluoroimmunometric assay (Delfia neonatal hTSH and T4 kits).Results: Ten neonates were missed by our screening programme (normal tT4 and TSH) and classified as false negatives; these infants were diagnosed later in life with central hypothyroidism. If we had measured TSH alone in our screening programme, we would have missed an additional 2 1 patients with low tT4 and normal TSH; of these, four were affected by central hypothyroidism and 17 were diagnosed within the second month of life as affected by primary hypothyroidism with delayed TSH rise.Conclusions: Simultaneous T4 and TSH measurements at neonatal screening can miss patients affected by central hypothyroidism. However, this screening procedure allows identification of cases of central hypothyroidism with low T4 values and those neonates affected by primary hypothyroidism with delayed TSH rise who we would have missed by using the TSH measure alone
Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children.
No full textSubjects and methods: Final height; parentally adjusted final height; the metacarpal index (MI) SIB. the inner and outer diameters: and the total cross-sectional area (CSA). cortical CSA. medullary CSA and bone strength (Bending Breaking Resistance Index (BBRI)) were evaluated at the metacarpal site in two cohorts of GH-deficient children. treated with two different doses of GH. Group 1. (38 patients) was treated with 0.16 mg/kg body weight per week of GH and group 2 (37 patients) with 0.3 mg/kg per week.
Results: At the end of treatment. with group 1 vs group 2. height SDS was -0.84 +/- 1.07 vs -0.46 +/- 0.76. and parentally adjusted height SDS was 0.14 +/- 1.08 vs 0.27 +/- 0.82. Parentally adjusted relative height gain was 1.14 +/- 0.89 vs 2.14 +/- 0.72 SDS (P < 0.000.1). MI SDS was 0.58 +/- 1.31. vs -0.42 +/- 1.54 (P < 0.005). MI SDS gain was 0.07 +/- 1.41 vs -0.35 +/- 1.85. There was no difference between groups in the outer and inner diameter, in the total and cortical CSAs, whereas medullary CSA was higher in group 2 (P < 0.05). BBRI was 10.02 +/- 5.37 vs 11.52 +/- 5.49cm(3), and BBRI gainwas 3.33 +/- 5.06 vs 6.88 +/- 6.65 (P=0.01). P values were assessed using student's t-test.
Conclusion: Higher GH doses result in a greater height gain and improved bone strength
Effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency
No full textstudy on the effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency
A four-year dose-response study of recombinant human fgrowth hormone treatment of growth hormone deficient children: effect on growth, bone growth and bone mineralization.
No full textEffect of Arginine Infusion on Ghrelin Secretion in Growth Hormone-Sufficient and GH-Deficient Children.
No full textBackground: The physiological link between ghrelin and growth hormone (GH) has not yet
been fully clarified. Furthermore, the existence of a negative feedback mechanism between
growth hormone–insulin-like growth factor (GH–IGF)-I axis and ghrelin and the influence of
amino acids on ghrelin secretion in children remain matters of debate.
Objectives: To understand the regulation of ghrelin secretion and clarify the relationship
between ghrelin and GH secretion in GH-deficient (GHD) and GH-sufficient (GHS) children
Patients and Methods: Ten GHD (male/female [M/F], 6/4; age [mean ± SEM], 10.7 ± 0.9 years)
and 10 GHS prepubertal children (M/F, 6/4; age [mean ± SEM], 10.3 ± 0.6 years), underwent an
arginine (ARG) test (infusion, 0.5 g/kg, iv). Levels of GH, total ghrelin, and acylated ghrelin
(AG) were assayed every 30 min from 0 to +120 min.
Results: Peak GH values were lower in GHD subjects than in GHS subjects (P < 0.0001). The
baseline levels, peak levels, or area under the curves (AUC) for total ghrelin and AG were
similar between GHD and GHS children. ARG infusion was followed by a slight to significant
decrease in total ghrelin levels, but not AG levels, both in GHD and GHS subjects with a nadir
at +30 min. No correlation was seen between GH, total ghrelin, or AG response and ARG
infusion.
Conclusions: Total ghrelin and AG levels seemed unaffected by GH status in prepubertal children.
ARG infusion was unable to blunt ghrelin secretion irrespective of GH status in childhood.
Moreover, since ARG influences GH secretion via modulation of somatostatin release,
ghrelin secretion seems to be partially refractory to somatostatin action
Effects of two different regimens of hGH therapy on bone mineral density of patients with GH deficiency.
No full text- …
